Tags

Type your tag names separated by a space and hit enter

Febuxostat (Uloric) for chronic treatment of gout.
Med Lett Drugs Ther. 2009 May 18; 51(1312):37-8.ML

Abstract

Febuxostat (Uloric--Takeda), a xanthine oxidase inhibitor, has been approved by the FDA for chronic management of hyperuricemia in patients with gout. It is the first drug marketed for treatment of gout in 40 years. Febuxostat is structurally unrelated to allopurinol, the only other commercially available inhibitor of xanthine oxidase. Xanthine oxidase inhibitors decrease serum urate concentrations by decreasing urate synthesis.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19448587

Citation

"Febuxostat (Uloric) for Chronic Treatment of Gout." The Medical Letter On Drugs and Therapeutics, vol. 51, no. 1312, 2009, pp. 37-8.
Febuxostat (Uloric) for chronic treatment of gout. Med Lett Drugs Ther. 2009;51(1312):37-8.
(2009). Febuxostat (Uloric) for chronic treatment of gout. The Medical Letter On Drugs and Therapeutics, 51(1312), 37-8.
Febuxostat (Uloric) for Chronic Treatment of Gout. Med Lett Drugs Ther. 2009 May 18;51(1312):37-8. PubMed PMID: 19448587.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Febuxostat (Uloric) for chronic treatment of gout. PY - 2009/5/19/entrez PY - 2009/5/19/pubmed PY - 2009/6/11/medline SP - 37 EP - 8 JF - The Medical letter on drugs and therapeutics JO - Med Lett Drugs Ther VL - 51 IS - 1312 N2 - Febuxostat (Uloric--Takeda), a xanthine oxidase inhibitor, has been approved by the FDA for chronic management of hyperuricemia in patients with gout. It is the first drug marketed for treatment of gout in 40 years. Febuxostat is structurally unrelated to allopurinol, the only other commercially available inhibitor of xanthine oxidase. Xanthine oxidase inhibitors decrease serum urate concentrations by decreasing urate synthesis. SN - 1523-2859 UR - https://www.unboundmedicine.com/medline/citation/19448587/Febuxostat__Uloric__for_chronic_treatment_of_gout_ L2 - http://www.medicalletter.org/scripts/articlefind.cgi?issue=1312&page=37 DB - PRIME DP - Unbound Medicine ER -